Latest news for Aclarion (NASDAQ:ACONW) Stock

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Aclarion Inc

My&nbsp;<a href="https://www.youtube.com/watch?v=VIlnM_wcw0w" onclick="javascript:window.open('https://www.youtube.com/watch?v=VIlnM_wcw0w', '_blank', 'noopener'); return false;" rel="noopener">favorite scene in the movie Arbitrage</a>&nbsp;(spoiler alert) is where Richard Gere&rsquo;s character, Robert Miller, negotiates the sale of his business to a rival, James Mayfield. Miller, who has become increasingly frustrated with the lengthy negotiation process, tells Mayfield that the deal is off and he is leaving. As he starts to walk away, Mayfield offers him $400 million for his business. Miller counters with $550 million. Mayfield comes back with $475 million. Then Miller makes a&nbsp;final&nbsp;offer of $525 million and tells Mayfield that the deal is off if he doesn&rsquo;t take it. Mayfield accepts.
Miller writes up the contract on the back of a restaurant menu and both men sign it. Following the signing, Miller has the following exchange with Mayfield:
<blockquote>Miller: Before I leave, what would you have paid?
Mayfield: 600 [million]. And, you would have taken?
Miller: 475.
Mayfield: So we made a good deal.
Miller: Yeah.
</blockquote>
Miller starts to leave the restaurant before coming back and saying, &ldquo;Actually I lied. I would&rsquo;ve taken 400.&rdquo;
I&rsquo;ve always remembered this scene because of how bad it makes Miller look. Here&rsquo;s a guy that just sold his fraudulent business (sorry for the spoiler) for $525 million and yet he still has the nerve to give a final &ldquo;F&mdash; you&rdquo; to the person that bought it from him. Despite Miller&rsquo;s questionable character, many would agree that he is a good negotiator. But, I don&rsquo;t.
In the world of negotiation, there seems to be this implicit assumption that you should always strive to get the best deal possible. There&rsquo;s this belief that the more value that you can extract from a situation, the better of a negotiator you are. While this might seem true in theory, I don&rsquo;t think it&rsquo;s true in practice.&nbsp;
The problem with thinking of negotiation as a zero sum game (i.e. your loss is my gain) is that it doesn&rsquo;t take into account the impact of&nbsp;time&nbsp;on your success. Yes, in a single negotiation (or a&nbsp;<a href="https://kstatelibraries.pressbooks.pub/economicsoffoodandag/chapter/__unknown__-7/#" onclick="javascript:window.open('https://kstatelibraries.pressbooks.pub/economicsoffoodandag/chapter/__unknown__-7/#', '_blank', 'noopener'); return false;" rel="noopener">one-shot game</a>&nbsp;as it&rsquo;s called), you should always try to get the best deal possible. But, most things in life aren&rsquo;t one-shot games. Most of the negotiations you will have throughout your life will happen with the same people over and over again. Whether that&rsquo;s your employer , your spouse, your friends, or someone else entirely, these aren&rsquo;t one-off scenarios. These are what economists call infinite games.
And the way you negotiate in an infinite game is&nbsp;different&nbsp;than the way you negotiate in a one-shot (or finite game). Because infinite games have future consequences. So, if you play an infinite game like you would play a finite game, you can lose out in the long run.&nbsp;
For example, imagine you and your partner are trying to figure out who&rsquo;s job it is to take out the trash and who&rsquo;s job it is to clean the dishes. You guys agree for you to take out the trash and for your partner to do the dishes. What a deal, right?&nbsp;Inside you are jumping with joy because you know that periodically taking out the trash is a far easier job than doing the dishes each day.&nbsp;
While you may have &ldquo;won&rdquo; in the short run, imagine what will happen over time. At first your partner may not say anything. After all, you guys agreed to it. But as the days and months go by, they may start to secretly resent you for doing much less work than them. And that resentment builds until one day it explodes into a fight.&nbsp;Is that what you want? Is this worth being a better negotiator? I think not.
The same kind of dynamic can unfold with your employer if you ask for a higher salary too soon or too often. You can sour the relationship and jeopardize your career. Of course, I am not telling you to take &ldquo;no&rdquo; for an answer when asking for a raise. However, I am warning about what can happen if you don&rsquo;t go about it in the right way.
This is why one of my favorite pieces of advice from Charlie Munger is, &ldquo;You don&rsquo;t need to take the last dollar.&rdquo; Munger realized that if a deal is good, it&rsquo;s good. Trying to squeeze every last penny out of such a situation rarely serve your interests. This is what hyper-optimizers do and it&rsquo;s&nbsp;<a href="https://ofdollarsanddata.com/why-you-shouldnt-optimize-your-life/" onclick="javascript:window.open('https://ofdollarsanddata.com/why-you-shouldnt-optimize-your-life/', '_blank', 'noopener'); return false;">a terrible way to live</a>. Trust me, I know.
If you are an optimizer/maximizer, you&rsquo;ll always be wondering if you could do better. You&rsquo;ll always be thinking about whether you got the best deal. Thankfully, there are a few ways to counteract this:
<ol>
<li>Think about the long-term. When you think about how something can turn out in the future, it&rsquo;s much easier to ignore the starting details. For example, if you knew Berkshire Hathaway Class A shares were one day going to be worth over $600,000 a share, would you care if you paid $5,000 or $6,000 upfront? Of course you wouldn&rsquo;t. I do these kinds of thought experiments all the time and it truly helps me be less of an optimizer.</li>
<li>Be content with what you have.&nbsp;Finding contentment with what you have is a far better use of your mental energy than thinking about what could be. It&rsquo;s far better to get a decent deal and move on mentally than strive for more and get hung up on whether you could do better.</li>
<li>Accept that you will never capture your full value.&nbsp;You&rsquo;ve probably heard that your employer will never pay you what you&rsquo;re worth, otherwise they wouldn&rsquo;t be profitable. Yes, this is true. But it&rsquo;s true for everyone else at the company too. Even someone like Jeff Bezos has only captured a fraction of the value that he has created by founding Amazon. When I worked at a consulting firm, my compensation was roughly equal to 20% of my billable revenue. This meant that 80% of my quantifiable value was not taken home by me. And that&rsquo;s fine. This is how it is for most people. The only people who this doesn&rsquo;t apply to are frankly, parasitic. They capture more value than they produce. This happens, but it&rsquo;s rare. Almost everyone creates more value than what they take home. The sooner you realize this, the easier it is to deal with these scenarios.</li>
</ol>
Ultimately, the best way to negotiate is to&nbsp;not&nbsp;take the last dollar. It&rsquo;s to always negotiate as if you&rsquo;re playing an infinite game. Of course, no game is truly infinite. But, you should act&nbsp;as if&nbsp;it is in almost all cases. Even when you know that an infinite game is ending (i.e. becoming finite), you should still pretend its infinite. Why? Because how you behave in those situations will follow you. It&rsquo;s your reputation you have to worry about. And your reputation is an infinite game. It lives on even after you&rsquo;re gone.
For example, both you and your employer know that one day you will no longer work there. It&rsquo;s a finite game, but both parties should treat it like an infinite game. Because, if your employer mistreated you after you stopped working there, imagine how current employees would feel about this. They wouldn&rsquo;t think too highly of their company and they might leave. By treating any game as finite, it can impact all the other games you are playing. This is why the simplest solution is to treat all games like infinite games. When you do that, you naturally set yourself up for success.
Negotiating is hard, but if you treat it like an infinite game, it makes it a whole lot easier. If you&rsquo;re interested in learning more on this topic, I highly recommend reading&nbsp;<a href="https://amzn.to/45RYMNY" onclick="javascript:window.open('https://amzn.to/45RYMNY', '_blank', 'noopener'); return false;" rel="noopener">Finite and Infinite Games</a>&nbsp;by James Carse. Thank you for reading.
If you liked this post, consider&nbsp;<a href="https://ofdollarsanddata.com/newsletter/" onclick="javascript:window.open('https://ofdollarsanddata.com/newsletter/', '_blank', 'noopener'); return false;">signing up for my newsletter</a>.

Personal Finance

General

Don't Take The Last Dollar

Atkore's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) short percent of float has fallen 8.24% since its last report. The company recently reported that it has 5.65 million shares sold short, which is 20.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Atkore Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151920_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Atkore has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Atkore's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Atkore's peer group average for short interest as a percentage of float is 10.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

ATKR

Looking Into Atkore's Recent Short Interest

Primerica's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) short percent of float has fallen 27.87% since its last report. The company recently reported that it has 472 thousand shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Primerica Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151915_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Primerica has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Primerica's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Primerica's peer group average for short interest as a percentage of float is 2.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Primerica's Recent Short Interest

Adient's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) short percent of float has risen 6.14% since its last report. The company recently reported that it has 5.14 million shares sold short, which is 8.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Adient Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151910_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Adient has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Adient's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Adient's peer group average for short interest as a percentage of float is 7.23%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ADNT

How Is The Market Feeling About Adient?

WIIM

ALLE

ROCK

UFPI

Shares of construction and building product companies are trading higher after store sales of building material and garden supplies rose 1.4% in June.

Macro Notification

News

U.S. State Dept Says Aware Of Reports Of Deaths Of Two U.S. Citizens In Thailand

B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and raises the price target from $64 to $67.

Price Target

Analyst Ratings

IONS

B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $67

Evercore ISI Group maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Outperform and raises the price target from $1620 to $2010, previously reported on June 13, 2024.

AVGO

Evercore ISI Group Maintains Outperform on Broadcom, Raises Price Target to $2010 - Previously Reported on June 13, 2024

B of A Securities analyst Eddie Leung maintains Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) with a Buy and lowers the price target from $140 to $128.

BIDU

B of A Securities Maintains Buy on Baidu, Lowers Price Target to $128

Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported better-than-expected <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39777515/goldman-sachs-strong-q2-performance-boosts-confidence-in-future-returns-says-jp-mor">results for its second quarter</a> on Monday.
Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion. The U.S. financial services giant reported GAAP EPS of $8.62, beating the consensus of $8.35, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Global Banking &amp; Markets revenues were $8.18 billion, up 14% year over year. Asset &amp; Wealth Management revenue was $3.88 billion for the second quarter of 2024, 27% higher than last year.
Provision for credit losses was $282 million for the second quarter, compared with losses of $615 million a year ago, reflecting net provisions related to the credit card portfolio (driven by net charge-offs).
David Solomon, Chairman and CEO, said, &#8220;We are pleased with our solid second-quarter results and our overall performance in the first half of the year, reflecting strong year-on-year growth in both Global Banking &amp; Markets and Asset &amp; Wealth Management.&#8221;
Goldman Sachs shares gained 2.1% to trade at $502.27 on Tuesday.
These analysts made changes to their price targets on Goldman Sachs after the company reported quarterly results.
<ul>
<li>Morgan Stanley analyst Betsy Graseck maintained Goldman Sachs with an Overweight rating and raised the price target from $475 to $513.</li>
<li>Oppenheimer analyst Chris Kotowski maintained Goldman Sachs with an Outperform rating and increased the price target from $504 to $559.</li>
<li>RBC Capital analyst Gerard Cassidy maintained the stock with a Sector Perform rating, while raising the price target from $435 to $500.</li>
<li>JP Morgan analyst Kian Abouhossein maintained the stock with an Overweight rating, while increasing the price target from $461 to $464.</li>
<li>Evercore ISI Group analyst Glenn Schorr maintained Goldman Sachs with an Outperform rating and raised the price target from $475 to $520.</li>
<li>Barclays analyst Jason Goldberg maintained the stock with an Overweight rating, while increasing the price target from $493 to $565.</li>
<li>Citigroup analyst Keith Horowitz maintained the stock with a Neutral rating and raised the price target from $460 to $485.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39789748/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Markets

Goldman Sachs Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Post Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/post#NYSE">POST</a>) has shown impressive performance lately, with shares gaining 20.9% year to date, marking a significant contrast to the industry&#39;s decline of 4.9%. The leading consumer-packaged goods company has adeptly managed pricing strategies to mitigate the impact of inflationary pressures, particularly sugar and labor costs.
Strategic acquisitions are further expanding Post Holdings&#39; market reach and have been pivotal in enhancing the company&#39;s market position and diversifying its revenue streams. Notable acquisitions, such as Perfection Pet, have strengthened the company&#39;s portfolio and contributed to its growth trajectory.
Thanks to its robust performance across segments, this Zacks Rank #3 (Hold) company has managed to surpass both the Zacks Consumer Staples sector and the S&amp;P 500&#39;s respective gains of 2% and 17%, respectively, in the year-to-date period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b8/71468.jpg?v=1122087196" />
Image Source: Zacks Investment Research
<h3>Decoding the Stock&#39;s Rally</h3>
Post Holdings is experiencing significant momentum driven by strategic initiatives and robust performance in its Post Consumer Brands segment. During the second quarter of fiscal 2024, this segment showcased a remarkable 77.9% rise in revenues, bolstered significantly by $460.7 million in sales from acquisitions. Furthermore, the company&#39;s pet food and grocery business delivered impressive results within this segment, driven by the successful expansion of its value offerings.
Buoyed by exceptional manufacturing performance, and strategic carryover pricing, Post Holdings&#39; pet food and grocery business not only met but exceeded market demands, contributing significantly to the company&#39;s overall performance. These factors underscore the effectiveness of Post Holdings&#39; growth strategies and its ability to capitalize on market opportunities.
The acquisition of Perfection Pet in December 2023 has significantly benefited Post Holdings, expanding its customer base and strengthening its position in the market. Additionally, other notable acquisitions such as Lacka Foods Limited, PL RTE Cereal Business, Almark Foods, Conagra&#39;s Peter Pan peanut butter brand, and select pet food brands from The J.M. Smucker Co have further supported Post Holdings&#39; growth strategy.
These acquisitions have not only expanded the company&#39;s brand lineup but also diversified its product offerings, enhancing its competitive edge in the consumer-packaged goods sector.
<h3>Unlocking Shareholder Value</h3>
Post Holdings&#39; robust cash flows enable it to engage in shareholder-friendly actions. In the second quarter of fiscal 2024, it repurchased 0.1 million shares for $103.88 million. This demonstrates the company&#39;s commitment to returning value to shareholders through buybacks.
Overall, these actions underscore Post Holdings&#39; strategic capital allocation approach focusing on enhancing shareholder returns while maintaining financial flexibility for future growth initiatives.
<h3>Hiccups on the Path</h3>
Despite the positive performance indicators, Post Holdings faces challenges in a tough macroeconomic environment. Escalated SG&amp;A expenses, inflationary pressures, intense competition, declines in restaurant foot traffic, and inventory reductions remain significant concerns for the company. These factors underline the importance of prudent management and strategic decision-making to navigate challenges effectively and maintain sustainable growth amid external pressures.
Additionally, Post Holdings stock is trading at a significant premium compared to the Zacks Food - Miscellaneous industry. Its forward 12-month P/E of 17.48X is higher than the industry&#39;s 15.42X.
While Post Holding&#39;s strategic initiatives keep it well positioned for further growth, investors might want to wait for a better entry point, given the near-term hurdles and stretched valuation. Post Holdings currently carries a Zacks Rank #3 (Hold).
<h3>3 Picks You Can&#39;t Miss</h3>
Here, we have highlighted three better-ranked stocks, namely, Colgate-Palmolive (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cl#NYSE">CL</a>), Church &amp; Dwight Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chd#NYSE">CHD</a>) and Ollie&#39;s Bargain Outlet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olli#NASDAQ">OLLI</a>).
Colgate-Palmolive, which manufactures and sells consumer products, currently carries a Zacks Rank #2 (Buy). CL delivered an earnings surprise of 4.4% in the trailing four quarters, on average.
The Zacks Consensus Estimate for Colgate-Palmolive&#39;s current fiscal-year sales and earnings suggests growth of 3.8% and nearly 9.3%, respectively, from the year-ago reported numbers.
Church &amp; Dwight Co. develops, manufactures and markets a broad range of household, personal care and specialty products. The company currently carries a Zacks Rank #2. CHD has a trailing four-quarter earnings surprise of 9.6%, on average.
The Zacks Consensus Estimate for Church &amp; Dwight&#39;s current fiscal-year sales and earnings suggests growth of 4.6% and 9.1%, respectively, from the year-ago reported numbers.
Ollie&#39;s Bargain, the extreme-value retailer of brand-name merchandise, currently carries a Zacks Rank #2. OLLI has a trailing four-quarter earnings surprise of 10.4%, on average.
The Zacks Consensus Estimate for Ollie&#39;s Bargain&#39;s current financial-year sales and earnings indicates a rise of around 7.9% and 12.0%, respectively, from the year-earlier levels.
<a href="https://www.zacks.com/stock/news/2302640/post-holdings-post-rallies-21-ytd-how-to-play-the-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2302640">To read this article on Zacks.com click here.</a>

Buybacks

OLLI

POST

Post Holdings Rallies 21% YTD: How to Play the Stock?

Lisata Therapeutics, Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lsta#NASDAQ">LSTA</a>) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treating a range of solid tumors.
Earlier this month, the company announced upbeat data from a preclinical study evaluating certepetide for treating intrahepatic cholangiocarcinoma, an aggressive form of cancer, with a poor prognosis.
Data from the study showed that treatment with certepetide combined with standard-of-care (SoC) chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma.
Certepetide is an investigational drug candidate that allows co-administered or tethered anti-cancer drugs to better penetrate solid tumors by activating a novel uptake pathway. The candidate has exhibited the potential to improve the tumor environment, thereby making tumors more responsive to immunotherapy.
Notably, the phase IIa BOLSTER study is currently investigating certepetide in combination with standard-of-care chemotherapy as a first-line treatment for cholangiocarcinoma.
The positive preclinical data underlines the potential of certepetide in treating human patients with intrahepatic cholangiocarcinoma.
As a result, LSTA is now looking to add another arm to the BOLSTER study, which will evaluate certepetide in combination with SoC chemoimmunotherapy for treating intrahepatic cholangiocarcinoma.
Shares of LSTA have rallied 33.7% year to date (YTD) against the industry&#39;s decline of 2.7%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/77/71467.jpg?v=633149196" />
Image Source: Zacks Investment Research
Certepetide is currently being evaluated as a combination therapy with various anti-cancer regimens in several early-to-mid-stage studies for treating multiple cancer indications, including metastatic pancreatic ductal adenocarcinoma.
The FDA granted an Orphan Drug designation to certepetide for treating osteosarcoma, a rare type of bone cancer, in April. The FDA also granted a Rare Pediatric Disease Designation to certepetide for treating osteosarcoma in March.
The FDA has previously granted Orphan Drug designation to certepetide for the treatment of pancreatic cancer and glioblastoma multiforme (GBM). The regulatory body has also granted a Fast Track designation to certepetide for pancreatic cancer.
Certepetide is also being studied for other forms of cancers, including pancreatic, esophageal, head and neck, appendiceal and colon cancers, as well as GBM.
Several clinical data readouts from various studies on certepetide are expected during the upcoming months, which, if successful, can significantly boost the company&#39;s growth prospect.
Progress with the ongoing studies and successful development of certepetide should continue the upward momentum for Lisata for the remainder of 2024.
<div class="chart_embed">
<h3>Lisata Therapeutics, Inc. Price</h3>
<img alt="Lisata Therapeutics, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/d2/1721136208.png" style="height:251px; width:531px" title="" />
Lisata Therapeutics, Inc. price | Lisata Therapeutics, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Lisata currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) and RAPT Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rapt#NASDAQ">RAPT</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, estimates for ANI Pharmaceuticals 2024 earnings per share have improved from $4.41 to $4.44. Earnings per share estimates for 2025 have improved from $4.85 to $5.42. Shares of ANIP have jumped 14.7% YTD.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 53.90%.
In the past 60 days, estimates for Adaptive Biotechnologies&#39; 2024 loss per share have narrowed from $1.30 to $1.29, while loss per share estimates for 2025 have narrowed from $1.08 to $1.02. Shares of ADPT have lost 17.7% YTD.
ADPT&#39;s earnings beat estimates in two of the trailing four quarters, meeting the same once and missing on the remaining occasion, the average surprise being 0.65%.
In the past 60 days, estimates for RAPT Therapeutics&#39; 2024 loss per share have narrowed from $2.94 to $2.93. Loss per share estimates for 2025 have narrowed from $2.06 to $2.05. Shares of RAPT have plunged 85.7% YTD.
RAPT&#39;s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%.
<a href="https://www.zacks.com/stock/news/2302707/lisata-lsta-stock-rallies-more-than-30-ytd-here-s-why?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2302707">To read this article on Zacks.com click here.</a>

Earnings Beats

Penny Stocks

Health Care

Small Cap

ADPT

ANIP

LSTA

RAPT

Lisata Stock Rallies More Than 30% YTD: Here's Why

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$6.00</td>
<td>$1.0 million</td>
<td>20.4K</td>
<td>69.3K</td>
</tr>
<tr>
<td>CHPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$2.50</td>
<td>$26.7K</td>
<td>560</td>
<td>5.6K</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$50.00</td>
<td>$42.3K</td>
<td>9.7K</td>
<td>3.2K</td>
</tr>
<tr>
<td>BLDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$200.00</td>
<td>$28.7K</td>
<td>1.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>RUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$75.0K</td>
<td>14.0K</td>
<td>886</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$200.00</td>
<td>$50.7K</td>
<td>1.2K</td>
<td>575</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$365.00</td>
<td>$181.7K</td>
<td>140</td>
<td>347</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$155.00</td>
<td>$30.0K</td>
<td>634</td>
<td>52</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$300.00</td>
<td>$54.1K</td>
<td>530</td>
<td>38</td>
</tr>
<tr>
<td>WCC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$180.00</td>
<td>$26.4K</td>
<td>5</td>
<td>22</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ACHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), we observe a call option trade with bearish sentiment. It expires in 94 day(s) on October 18, 2024. Parties traded 33565 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $1.0 million, with a price of $30.0 per contract. There were 20414 open contracts at this strike prior to today, and today 69340 contract(s) were bought and sold. 
• Regarding CHPT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on August 2, 2024. Parties traded 1576 contract(s) at a $2.50 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $17.0 per contract. There were 560 open contracts at this strike prior to today, and today 5607 contract(s) were bought and sold. 
• Regarding UAL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), we observe a put option sweep with bullish sentiment. It expires in 31 day(s) on August 16, 2024. Parties traded 92 contract(s) at a $50.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $42.3K, with a price of $460.0 per contract. There were 9704 open contracts at this strike prior to today, and today 3264 contract(s) were bought and sold. 
• Regarding BLDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>), we observe a call option trade with bearish sentiment. It expires in 31 day(s) on August 16, 2024. Parties traded 205 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $28.7K, with a price of $140.0 per contract. There were 1212 open contracts at this strike prior to today, and today 1212 contract(s) were bought and sold. 
• For RUN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>), we notice a call option trade that happens to be bullish, expiring in 185 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $75.0K, with a price of $300.0 per contract. There were 14067 open contracts at this strike prior to today, and today 886 contract(s) were bought and sold. 
• For BA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), we notice a call option sweep that happens to be bullish, expiring in 122 day(s) on November 15, 2024. This event was a transfer of 50 contract(s) at a $200.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $50.7K, with a price of $1015.0 per contract. There were 1230 open contracts at this strike prior to today, and today 575 contract(s) were bought and sold. 
• Regarding CAT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on July 26, 2024. Parties traded 460 contract(s) at a $365.00 strike. The total cost received by the writing party (or parties) was $181.7K, with a price of $395.0 per contract. There were 140 open contracts at this strike prior to today, and today 347 contract(s) were bought and sold. 
• Regarding UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>), we observe a call option sweep with bearish sentiment. It expires in 94 day(s) on October 18, 2024. Parties traded 69 contract(s) at a $155.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $435.0 per contract. There were 634 open contracts at this strike prior to today, and today 52 contract(s) were bought and sold. 
• Regarding FDX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), we observe a call option trade with bearish sentiment. It expires in 549 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $54.1K, with a price of $5415.0 per contract. There were 530 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold. 
• For WCC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>), we notice a put option trade that happens to be bearish, expiring in 3 day(s) on July 19, 2024. This event was a transfer of 150 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $26.4K, with a price of $176.0 per contract. There were 5 open contracts at this strike prior to today, and today 22 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ACHR

BLDR

CHPT

10 Industrials Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$255.00</td>
<td>$60.5K</td>
<td>9.4K</td>
<td>56.5K</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$9.00</td>
<td>$26.0K</td>
<td>8.3K</td>
<td>3.3K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$205.00</td>
<td>$813.2K</td>
<td>24.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>QS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$8.00</td>
<td>$30.3K</td>
<td>6.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>W</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$55.00</td>
<td>$30.8K</td>
<td>3.4K</td>
<td>408</td>
</tr>
<tr>
<td>GME</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/02/24</td>
<td>$44.00</td>
<td>$25.7K</td>
<td>0</td>
<td>186</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$41.00</td>
<td>$55.2K</td>
<td>15.0K</td>
<td>150</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$340.00</td>
<td>$42.4K</td>
<td>481</td>
<td>79</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/02/24</td>
<td>$367.50</td>
<td>$44.3K</td>
<td>0</td>
<td>74</td>
</tr>
<tr>
<td>WSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$115.00</td>
<td>$157.0K</td>
<td>96</td>
<td>46</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on July 19, 2024. Parties traded 100 contract(s) at a $255.00 strike. The total cost received by the writing party (or parties) was $60.5K, with a price of $605.0 per contract. There were 9480 open contracts at this strike prior to today, and today 56502 contract(s) were bought and sold. 
• For XPEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), we notice a call option sweep that happens to be bearish, expiring in 3 day(s) on July 19, 2024. This event was a transfer of 1000 contract(s) at a $9.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.0K, with a price of $26.0 per contract. There were 8329 open contracts at this strike prior to today, and today 3357 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option trade that happens to be bullish, expiring in 31 day(s) on August 16, 2024. This event was a transfer of 1749 contract(s) at a $205.00 strike. The total cost received by the writing party (or parties) was $813.2K, with a price of $465.0 per contract. There were 24916 open contracts at this strike prior to today, and today 1509 contract(s) were bought and sold. 
• For QS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>), we notice a call option sweep that happens to be bullish, expiring in 31 day(s) on August 16, 2024. This event was a transfer of 204 contract(s) at a $8.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $30.3K, with a price of $149.0 per contract. There were 6250 open contracts at this strike prior to today, and today 1215 contract(s) were bought and sold. 
• For W (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>), we notice a put option sweep that happens to be bearish, expiring in 3 day(s) on July 19, 2024. This event was a transfer of 315 contract(s) at a $55.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $97.0 per contract. There were 3433 open contracts at this strike prior to today, and today 408 contract(s) were bought and sold. 
• Regarding GME (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), we observe a put option trade with neutral sentiment. It expires in 17 day(s) on August 2, 2024. Parties traded 15 contract(s) at a $44.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $1717.0 per contract. There were 0 open contracts at this strike prior to today, and today 186 contract(s) were bought and sold. 
• Regarding GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), we observe a call option sweep with bullish sentiment. It expires in 66 day(s) on September 20, 2024. Parties traded 60 contract(s) at a $41.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $55.2K, with a price of $920.0 per contract. There were 15016 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>), we notice a call option trade that happens to be neutral, expiring in 185 day(s) on January 17, 2025. This event was a transfer of 15 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $42.4K, with a price of $2830.0 per contract. There were 481 open contracts at this strike prior to today, and today 79 contract(s) were bought and sold. 
• Regarding HD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), we observe a put option sweep with neutral sentiment. It expires in 17 day(s) on August 2, 2024. Parties traded 70 contract(s) at a $367.50 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $649.0 per contract. There were 0 open contracts at this strike prior to today, and today 74 contract(s) were bought and sold. 
• For WSM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>), we notice a call option sweep that happens to be neutral, expiring in 31 day(s) on August 16, 2024. This event was a transfer of 34 contract(s) at a $115.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $157.0K, with a price of $4575.0 per contract. There were 96 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

TSLA

XPEV

10 Consumer Discretionary Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Information Technology sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$127.00</td>
<td>$33.8K</td>
<td>15.3K</td>
<td>68.8K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$30.00</td>
<td>$209.8K</td>
<td>12.8K</td>
<td>8.9K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$300.00</td>
<td>$97.5K</td>
<td>55.0K</td>
<td>4.9K</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$900.00</td>
<td>$48.2K</td>
<td>2.8K</td>
<td>3.7K</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$18.50</td>
<td>$30.0K</td>
<td>172</td>
<td>2.1K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$1700.00</td>
<td>$37.2K</td>
<td>882</td>
<td>1.3K</td>
</tr>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/26/24</td>
<td>$450.00</td>
<td>$35.6K</td>
<td>1.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$52.0K</td>
<td>6.2K</td>
<td>879</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$140.00</td>
<td>$27.5K</td>
<td>5.8K</td>
<td>441</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$180.00</td>
<td>$44.5K</td>
<td>1.2K</td>
<td>402</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on July 19, 2024. Parties traded 162 contract(s) at a $127.00 strike. The total cost received by the writing party (or parties) was $33.8K, with a price of $209.0 per contract. There were 15310 open contracts at this strike prior to today, and today 68866 contract(s) were bought and sold. 
• For MARA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), we notice a call option sweep that happens to be bearish, expiring in 31 day(s) on August 16, 2024. This event was a transfer of 1221 contract(s) at a $30.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $209.8K, with a price of $172.0 per contract. There were 12852 open contracts at this strike prior to today, and today 8905 contract(s) were bought and sold. 
• Regarding AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we observe a call option trade with bearish sentiment. It expires in 185 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $97.5K, with a price of $195.0 per contract. There were 55043 open contracts at this strike prior to today, and today 4915 contract(s) were bought and sold. 
• Regarding SMCI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on July 19, 2024. Parties traded 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $48.2K, with a price of $2410.0 per contract. There were 2876 open contracts at this strike prior to today, and today 3741 contract(s) were bought and sold. 
• Regarding CLSK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on July 19, 2024. Parties traded 1000 contract(s) at a $18.50 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $30.0 per contract. There were 172 open contracts at this strike prior to today, and today 2110 contract(s) were bought and sold. 
• Regarding MSTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on July 19, 2024. Parties traded 11 contract(s) at a $1700.00 strike. The total cost received by the writing party (or parties) was $37.2K, with a price of $3383.0 per contract. There were 882 open contracts at this strike prior to today, and today 1344 contract(s) were bought and sold. 
• For MSFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), we notice a put option trade that happens to be neutral, expiring in 10 day(s) on July 26, 2024. This event was a transfer of 46 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $775.0 per contract. There were 1832 open contracts at this strike prior to today, and today 1138 contract(s) were bought and sold. 
• Regarding CORZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), we observe a call option sweep with bearish sentiment. It expires in 185 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $7.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 6208 open contracts at this strike prior to today, and today 879 contract(s) were bought and sold. 
• For MU (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), we notice a call option trade that happens to be bearish, expiring in 66 day(s) on September 20, 2024. This event was a transfer of 50 contract(s) at a $140.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $550.0 per contract. There were 5833 open contracts at this strike prior to today, and today 441 contract(s) were bought and sold. 
• Regarding IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), we observe a put option sweep with neutral sentiment. It expires in 94 day(s) on October 18, 2024. Parties traded 72 contract(s) at a $180.00 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $44.5K, with a price of $619.0 per contract. There were 1249 open contracts at this strike prior to today, and today 402 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

MARA

MSFT

MSTR

NVDA

SMCI

10 Information Technology Stocks With Whale Alerts In Today's Session

LECO

Shares of machine companies are trading higher following Core Retail Sales and Retail Sales economic data. Also, strength may be due to trader optimism that the Fed will cut rates.

Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) has outperformed the market over the past 15 years by 1.02% on an annualized basis producing an average annual return of 13.57%. Currently, Allstate has a market capitalization of $44.61 billion. 
Buying $1000 In ALL: If an investor had bought $1000 of ALL stock 15 years ago, it would be worth $6,848.46 today based on a price of $169.02 for ALL at the time of writing.
<h3>Allstate's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151244_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $6,800 Today

United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) has outperformed the market over the past 15 years by 6.59% on an annualized basis producing an average annual return of 19.14%. Currently, United Airlines Holdings has a market capitalization of $15.28 billion. 
Buying $1000 In UAL: If an investor had bought $1000 of UAL stock 15 years ago, it would be worth $12,490.59 today based on a price of $46.47 for UAL at the time of writing.
<h3>United Airlines Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151240_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning United Airlines Holdings Stock In The Last 15 Years

Scotts Miracle-Gro U.S. Consumer Business Pursuing Growth Opportunities At Emerging Touchpoints; Expects $150M In Supply Chain Cost Savings Over Next Three Years; Company Aims For 3% Average Annual Net Sales Growth From Fiscal 2025 Through Fiscal 2027

Deep-pocketed investors have adopted a bullish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 56% leaning bullish and 43% bearish. Among these notable options, 8 are puts, totaling $387,822, and 8 are calls, amounting to $411,975.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $280.0 for Applied Mat over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Applied Mat's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Applied Mat's significant trades, within a strike price range of $135.0 to $280.0, over the past month.
<h3>Applied Mat Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721151117_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$49.4</td>
<td>$47.05</td>
<td>$47.87</td>
<td>$250.00</td>
<td>$100.6K</td>
<td>940</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$23.8</td>
<td>$23.45</td>
<td>$23.5</td>
<td>$260.00</td>
<td>$86.9K</td>
<td>15</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$95.25</td>
<td>$93.75</td>
<td>$94.32</td>
<td>$150.00</td>
<td>$84.8K</td>
<td>53</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$2.28</td>
<td>$2.21</td>
<td>$2.27</td>
<td>$240.00</td>
<td>$79.6K</td>
<td>1.3K</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.27</td>
<td>$1.25</td>
<td>$1.25</td>
<td>$235.00</td>
<td>$70.3K</td>
<td>513</td>
<td style="text-align: right;">54</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Having examined the options trading patterns of Applied Mat, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Applied Mat's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,825,822, with AMAT's price down by -0.58%, positioned at $244.12.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<h3>What The Experts Say On Applied Mat</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $286.25.
<ul>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Applied Mat, targeting a price of $275. </li>
<li>Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Applied Mat with a target price of $300. </li>
<li>Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Applied Mat with a target price of $290. </li>
<li>An analyst from Wells Fargo has decided to maintain their Overweight rating on Applied Mat, which currently sits at a price target of $280. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Mat options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AMAT

Applied Mat Unusual Options Activity For July 16

Press Releases

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Financing

Aclarion Announces Pricing of $3.0 Million Public Offering

Aclarion Announces Closing of $3.0 Million Public Offering

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

ACON

ACONW

Aclarion

American Well Corporation Class A Common Stock

American Well

Augmedix

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Schrodinger

Sharecare

Simulations Plus

Sophia Genetics

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solns

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

Aclarion, Inc.,&nbsp;(&quot;Aclarion&quot; or the &quot;Company&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW))))),&nbsp;a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today an additional key milestone with their second payer coverage of Nociscan by Aviva in London, UK in conjunction with The London Clinic, one of the UK&#39;s largest and most renowned independent hospitals. Aviva is a leading provider of private medical insurance in the UK and joins private medical insurance provider, AXA, in covering Nociscan for patients suffering from chronic low back pain.

&quot;This second payer coverage decision builds the momentum we expect to see in markets once one payer recognizes the advantages of paying for Nociscan,&quot; said Brent Ness, CEO of Aclarion. &quot;When you look at other diagnostic companies that market imaging combined with AI decision support solutions, you tend to see steady product adoption and value creation once payer coverage decisions are secured. HeartFlow in the cardiology space is a perfect example. Similar to Aclarion, they received their first payer coverage decision in the UK and were able to parlay that into a steady march towards standard of care and tremendous value creation for investors. I was a member of the early commercial development team at HeartFlow and intend to apply the same successful formula to Aclarion where we are addressing the larger market of low back pain. We welcome the second vote of confidence and key validation from UK payers and look forward to more.&quot;

In the UK, self-pay and private medical insurance are estimated to represent nearly&nbsp;70%&nbsp;of private hospital revenues, with private medical insurance becoming increasingly popular. Aviva is one of the four leading private medical insurers in the UK with an estimated&nbsp;14%&nbsp;of the private medical insurance market and an estimated 1.2 million insured customers. By joining AXA, the 2nd&nbsp;largest private medical insurer with roughly a&nbsp;30%&nbsp;market share and 3 million covered lives, Nociscan is now available to&nbsp;45%&nbsp;of patients with private insurance in the greater London area.

The London Clinic and their expert spine physicians have adopted Nociscan as an important decision support tool to be used when diagnosing and treating their chronic low back pain patients. Low back pain has been estimated to affect up to one third of the UK adult population each year. Aclarion&#39;s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient&#39;s low back pain.

Aclarion's Nociscan Gains Second Payer Coverage in UK, Enhancing Chronic Low Back Pain Diagnosis

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Aclarion

News

Latest news for Aclarion (NASDAQ:ACONW) Stock

Tuesday, July 09, 2024

Thursday, January 04, 2024

People Also Watch